Noa Ruhrman-Shahar

Dr. Noa Ruhrman-Shahar

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
LBLina Basel-Salmon
Lina Basel-Salmon
NRNoa Ruhrman-Shahar
Noa Ruhrman-Shahar
OBOrtal Barel
Ortal Barel
OHOfir Hagari
Ofir Hagari
DMDina Marek-Yagel
Dina Marek-Yagel
MSMordechai Shohat
Mordechai Shohat

12 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Shoshana Revel-VilkShoshana Revel-Vilk
Shoshana Revel-Vilk
RMRoyston Mansfield
Royston Mansfield
NFNeta Feder-Krengel
Neta Feder-Krengel
NMNoya Machtiger-Azoulay
Noya Machtiger-Azoulay
DKDavid John Kuter
David John Kuter
Ari ZimranAri Zimran
Ari Zimran
Taliglucerase alfa is an enzyme replacement therapy approved for Gaucher disease. We assessed the duration/compliance/safety of such home infusions in commercial use in four countries where home infusion programs are available. The treatment duration/compliance study included 173 patients (Israel, 58; US, 61; Brazil, 48; Australia, 6) who received ≥1 taliglucerase alfa home infusion through 6/2021. The median age at home therapy initiation was 38 (range, 2–87) years; 58% were females. The median treatment duration (at home) was 2.7 (range, 0.04–9.0) years. The annual compliance rate was stable (≥95%) throughout the study period. A search of the Pfizer global safety database (through 6/2021), identified 19 adverse events (AEs) as related to “definite home use” and 14 to “possible home use” of taliglucerase alfa; 42.4% of these AEs were serious; none were fatal. Twelve serious AEs in five separate case reports were considered treatment related: one case of chest discomfort/pain and hypertension and one case of erythema associated with a toe blister, for which causality could not be excluded; pain in extremity; projectile vomiting and chills, alongside excessive eye blinking; and an infusion-related AE (pruritus). In conclusion, this real-life global study demonstrated that taliglucerase alfa home infusions are safe with high compliance rates.

16 July 2025 in Genetics in Medicine
Verified
Journal Article
Closed access
RGRotem Greenberg
Rotem Greenberg
NANoa Shefer Averbuch
Noa Shefer Averbuch
LSLena Sagi-Dain
Lena Sagi-Dain
IMIdit Maya
Idit Maya
NRNoa Ruhrman-Shahar
Noa Ruhrman-Shahar
SSShay Ben Shachar
Shay Ben Shachar

1 February 2025 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
NRNoa Ruhrman-Shahar
Noa Ruhrman-Shahar
DYDina Marek- Yagel
Dina Marek- Yagel
RGRotem Greenberg
Rotem Greenberg
OIOfer Isakov
Ofer Isakov
MNMichal Naftali
Michal Naftali
SBShay Ben-Shachar
Shay Ben-Shachar

24 September 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
NRNoa Ruhrman-Shahar
Noa Ruhrman-Shahar
NBNurit Assia Batzir
Nurit Assia Batzir
GLGabriel Arie Lidzbarsky
Gabriel Arie Lidzbarsky
LBLily Bazak
Lily Bazak
NMNurit Magal
Nurit Magal
LSLina Basel Salmon
Lina Basel Salmon

26 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Ari ZimranAri Zimran
Ari Zimran
JBJaco Botha
Jaco Botha
RERichard Eastell
Richard Eastell
Can FiciciogluCan Ficicioglu
Can Ficicioglu
RFRichard D. Finkelman
Richard D. Finkelman
DHDerralynn Hughes
Derralynn Hughes
Background: Despite the availability of effective therapies for Gaucher disease (GD), management of skeletal disease manifestations remains challenging. Methods: This phase 4 SHP-GCB-402 study evaluated the effect of velaglucerase alfa on lumbar spine (LS) bone outcomes in patients with type 1 GD. Results: Twenty-one patients with documented bone pathology received ≥1 dose of velaglucerase alfa 60 U/kg; 16 completed this study. The primary endpoint—change from baseline to 24 months in an LS bone mineral density (BMD) Z-score measured by dual-energy X-ray absorptiometry—showed a numerical improvement from baseline (mean [SD] −1.93 [0.88]) to 24 months (−1.76 [1.00]), although statistical significance was not reached (p = 0.1077). These changes are not consistent with previous velaglucerase alfa studies. To contextualize these findings, a pooled analysis of 24-month data from previous velaglucerase alfa trials was conducted. In this cohort (n = 40), a statistically significant mean (SD) increase in the LS BMD Z-score of 0.55 (0.58; p < 0.0001) was observed, supporting the therapeutic potential of velaglucerase alfa in improving skeletal outcomes. Additionally, SHP-GCB-402 demonstrated a significant reduction in the bone marrow burden (BMB) score (mean change from baseline: −3.0 [2.27]; p = 0.0005), indicating a positive effect on bone marrow infiltration. All patients experienced ≥1 treatment-emergent adverse event, mostly of mild/moderate severity. Conclusions: The observed numerical improvements in BMD and significant improvements in BMB in SHP-GCB-402 along with pooled BMD data suggest that velaglucerase alfa may confer skeletal benefits while maintaining a consistent safety profile.